Netarsudil Ophthalmic Solution Phase 3 Clinical Trial Highlights Aerie and Santen Pharmaceutical Co., Ltd. ("Santen") announced an exclusive collaboration and license agreement for Rhopressa ® and Rocklatan ® (netarsudil and latanoprost ophthalmic solution 0.02%/0.0005%) in Japan and several other Asian countries in October 2020. As part of this agreement, Santen is responsible for all regulatory process and commercialization related to the products in the territories covered by the agreement; however, Aerie and Santen collaborated on this first Phase 3 clinical trial for Rhopressa ® in Japan, which they co-funded. About Aerie Pharmaceuticals, Inc. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases.